HK1181642A1 - 以受體相關蛋白 肽-岩藻糖苷酶抑制劑偶聯物治療肝病症的方法 - Google Patents

以受體相關蛋白 肽-岩藻糖苷酶抑制劑偶聯物治療肝病症的方法

Info

Publication number
HK1181642A1
HK1181642A1 HK13108892.7A HK13108892A HK1181642A1 HK 1181642 A1 HK1181642 A1 HK 1181642A1 HK 13108892 A HK13108892 A HK 13108892A HK 1181642 A1 HK1181642 A1 HK 1181642A1
Authority
HK
Hong Kong
Prior art keywords
rap
peptide
associated protein
treating liver
receptor associated
Prior art date
Application number
HK13108892.7A
Other languages
English (en)
Inventor
Todd C Zankel
Original Assignee
Raptor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raptor Pharmaceuticals Inc filed Critical Raptor Pharmaceuticals Inc
Publication of HK1181642A1 publication Critical patent/HK1181642A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HK13108892.7A 2010-01-28 2013-07-31 以受體相關蛋白 肽-岩藻糖苷酶抑制劑偶聯物治療肝病症的方法 HK1181642A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29917710P 2010-01-28 2010-01-28
PCT/US2011/022917 WO2011094536A1 (en) 2010-01-28 2011-01-28 Method for treating liver disorders with receptor associated protein ( irp) peptide-fucosidase inhibitor conjugates

Publications (1)

Publication Number Publication Date
HK1181642A1 true HK1181642A1 (zh) 2013-11-15

Family

ID=44319804

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13108892.7A HK1181642A1 (zh) 2010-01-28 2013-07-31 以受體相關蛋白 肽-岩藻糖苷酶抑制劑偶聯物治療肝病症的方法

Country Status (11)

Country Link
US (1) US20110189084A1 (zh)
EP (1) EP2528613B1 (zh)
JP (2) JP6170675B2 (zh)
KR (1) KR101784539B1 (zh)
CN (1) CN102905716B (zh)
AU (1) AU2011210756B2 (zh)
CA (1) CA2788175A1 (zh)
ES (1) ES2555555T3 (zh)
HK (1) HK1181642A1 (zh)
TW (1) TWI558397B (zh)
WO (1) WO2011094536A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
RU2474423C1 (ru) * 2011-12-20 2013-02-10 Федеральное государственное бюджетное учреждение науки Институт общей физики им. А.М. Прохорова Российской академии наук (ИОФ РАН) Способ лечения метастазов печени
US10442868B2 (en) * 2013-03-14 2019-10-15 Rhode Island Hospital, A Lifespan-Partner Treating hepatitis B virus infections by administering receptor associated protein (RAP)
MX2018001315A (es) 2015-07-30 2018-08-15 Horizon Orphan Llc Inhibidores de fucosidasa.
US20220213058A1 (en) * 2019-05-10 2022-07-07 Alectos Therapeutics Inc. Non-lysosomal glucosylceramidase inhibitors and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4391904A (en) * 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US5186941A (en) 1983-05-06 1993-02-16 Vestar, Inc. Vesicle formulation for the controlled release of therapeutic agents
US5096909A (en) * 1989-06-27 1992-03-17 Monsanto Company Fucosidase inhibitor
US5153325A (en) * 1989-06-27 1992-10-06 Monsanto Company Fucosidase inhibitor
US5017704A (en) * 1989-06-27 1991-05-21 Monsanto Company Fucosidase inhibitor
US5100797A (en) * 1989-06-27 1992-03-31 Monsanto Company Fucosidase inhibitors
ZA912588B (en) * 1990-04-12 1992-01-29 Merrell Dow Pharma Novel alpha-mannosidase and fucosidase inhibitors
US5240707A (en) * 1990-04-12 1993-08-31 Merrell Dow Pharma Alpha-mannosidase and fucosidase inhibitors
US5474766A (en) * 1992-12-18 1995-12-12 Washington University Methods and compositions for inhibition of hepatic clearance of tissue-type plasminogen activator
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US6589954B1 (en) * 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ATE382351T1 (de) * 1999-08-10 2008-01-15 Univ Oxford Langkettige n-alkyl verbindungen und deren oxa- derivate zur verwendung als anitvirale mittel
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
US20040176320A1 (en) * 2001-06-29 2004-09-09 Jari Natunen Use of at least one glycoinhibitor substance
US6852842B2 (en) 2002-08-26 2005-02-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for functional kidney imaging using small dendrimer contrast agents
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
WO2005002515A2 (en) * 2003-06-20 2005-01-13 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US20060198819A1 (en) 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
JP2009506136A (ja) 2005-07-18 2009-02-12 ザ スクリプス リサーチ インスティテュート 両親媒性デンドリマーの製法
US8188563B2 (en) 2006-07-21 2012-05-29 The Regents Of The University Of California Shallow-trench-isolation (STI)-bounded single-photon CMOS photodetector
CA2663377A1 (en) * 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
US20080116171A1 (en) * 2006-11-22 2008-05-22 Clarkson University Method For The Preferential Polishing Of Silicon Nitride Versus Silicon Oxide
KR101801454B1 (ko) * 2007-03-21 2017-11-24 랩터 파마슈티컬스 인코포레이티드 환형의 수용체-연관된 단백질(ｒａｐ) 펩티드
US8236753B2 (en) * 2007-12-10 2012-08-07 The Brigham And Women's Hospital, Inc. RAP variants for drug delivery and methods of use thereof
US8252834B2 (en) 2008-03-12 2012-08-28 The Regents Of The University Of Michigan Dendrimer conjugates

Also Published As

Publication number Publication date
AU2011210756A1 (en) 2012-08-16
US20110189084A1 (en) 2011-08-04
CN102905716B (zh) 2016-06-01
TW201132343A (en) 2011-10-01
WO2011094536A1 (en) 2011-08-04
EP2528613A1 (en) 2012-12-05
TWI558397B (zh) 2016-11-21
JP2013518128A (ja) 2013-05-20
AU2011210756B2 (en) 2016-11-03
EP2528613B1 (en) 2015-10-21
KR20130025866A (ko) 2013-03-12
CA2788175A1 (en) 2011-08-04
JP2016145231A (ja) 2016-08-12
KR101784539B1 (ko) 2017-10-11
JP6170675B2 (ja) 2017-07-26
ES2555555T3 (es) 2016-01-04
CN102905716A (zh) 2013-01-30
EP2528613A4 (en) 2013-06-05

Similar Documents

Publication Publication Date Title
HRP20181558T1 (hr) Fuzijski proteini za liječenje metaboličkih poremećaja
HK1157663A1 (zh) 靶定補體蛋白 的抗體的組合物和方法
HK1192579A1 (zh) 組合物及使用了該組合物的部件的臨時固定方法
IL219914A (en) In the history of 3,1-diphenylprop-2-and-1-one for the treatment of liver disorders
EP2729123A4 (en) CANNABINOID RECEPTOR BINDER AND COMPOSITIONS THEREFOR AND METHOD THEREFOR
EP2558115A4 (en) METHODS OF TREATING METABOLIC DISORDERS USING FGF
DK2429417T3 (da) Apparat til påføring af kirurgisk fastgørelseselement
EP2798559A4 (en) METHODS AND APPARATUS FOR OPTIMIZATION OF CONFIDENCE STARTING
EP2558109A4 (en) METHOD FOR TREATING HARD TUMORS
PL2514873T3 (pl) Sposób i system do nanoszenia nawierzchni drogowej
HUE048639T2 (hu) Eljárás DLBCL kezelésére
EP2429530A4 (en) METHOD AND COMPOSITIONS FOR TREATING DEGENERATIVE AND ISCHEMIC ILLNESSES
EP2323681A4 (en) METHODS OF TREATING VIRAL CONDITIONS
IL232870A0 (en) Methods for selective quantification of cell aggregates
ZA201100304B (en) Method for cloning avian-derived antibodies
PL2242769T3 (pl) Przeciwciała przeciw domenie ec1 kadheryny 11 do leczenia zapalnych zaburzeń stawów
EP2654749A4 (en) PROCESS FOR TREATING COPD
EP2391372A4 (en) ESTROGENIC RECEPTOR-BASED CANCER TREATMENT METHODS BY INHIBITING X1 BOXING BINDING PROTEIN (XBP1)
HK1181642A1 (zh) 以受體相關蛋白 肽-岩藻糖苷酶抑制劑偶聯物治療肝病症的方法
GB201010359D0 (en) Compounds for treating proliferative disorders
EP2566478A4 (en) PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPERTENSION
EP2743683B8 (en) Method for desulfurizing hot metal
GB2486713B (en) Pharmaceutical composition for treating urinary system disorders
HK1201461A1 (zh) 用於治療糖尿病和其他退行性神經內分泌疾病或失調的方法和組合物
PL393756A1 (pl) Sposób modyfikacji asfaltu

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210126